{
  "docId": "019de070-c58c-706c-98f1-9eec26811648",
  "docSlug": "2a1e5b2d3a1cb25fe50abb3e75ae9bdf",
  "documentTitle": "Alkermes | Investor Day Presentation Deck | 144 slides",
  "authorId": "alkermes",
  "authorName": "Alkermes",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 60,
  "pageCount": 132,
  "prevPage": 59,
  "nextPage": 61,
  "slideType": "comparison_table",
  "function": "present_solution",
  "density": "sparse",
  "nDataPoints": 0,
  "notes": "Uses a Venn-like diagram to contrast existing therapy strategies with new development strategies.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de070-c58c-706c-98f1-9eec26811648/60",
  "deckHref": "/decks/019de070-c58c-706c-98f1-9eec26811648",
  "deckJsonHref": "/decks/019de070-c58c-706c-98f1-9eec26811648.json",
  "deckAnchorHref": "/decks/019de070-c58c-706c-98f1-9eec26811648#slide-60",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.9,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "diagram",
      "text": "Comparison of CPI-Approved vs Unapproved/Post-Failure strategies",
      "attrs": null,
      "subkind": "other",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2d36aeb2-96d9-4bee-9a4f-9f2ada2e9409",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.05,
        "y": 0.88
      },
      "kind": "source-note",
      "text": "*Granted Orphan Drug Designation; PROC = Platinum-Resistant Ovarian Cancer; CPI = Checkpoint Inhibitors",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "67c8ed3d-9ef9-4584-af6d-0ede0960f39a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Clinical Development Strategy Focused on Difficult to Treat Cancers With Clear Unmet Need",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "344826e6-6c5c-4dc4-b646-8706ee507321",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "comparison-frame",
      "slug": null,
      "matchId": "18f6442a-1565-450a-85e2-7bfaf9c7cb3a",
      "evidence": "The slide explicitly uses 'VS.' to contrast two strategic approaches.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 69,
      "from": 55,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "59dd9c04-c6d4-46f5-9a3a-eaa6b3829180",
      "evidence": "Slides 55-69 detail the development and potential of Nemvaleukin alfa.",
      "position": 1,
      "objective": "To present Nemvaleukin alfa as a potential game-changer in cancer treatment",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.8,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}